Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen P Peters

Showing results (21-30 of 210) with videos related to

Pageof 21
Sort By:
The Journal of Allergy and Clinical Immunology|November 10, 2009
The irreversible component of persistent asthmaRodolfo M Pascual, Stephen P Peters
American Journal of Respiratory and Critical Care Medicine|March 27, 2007
Update in asthma 2006Wendy C Moore, Stephen P Peters
Current Opinion in Pharmacology|May 11, 2010
Beta-2 adrenergic agonists: focus on safety and benefits versus risksVictor E Ortega, Stephen P Peters
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|March 24, 2010
Is the maintenance and reliever approach the answer?John J Oppenheimer, Stephen P Peters
Drug Discovery Today|December 27, 2005
Novel and emerging therapies for asthmaThomas M Leath, Manav Singla, Stephen P Peters
The Journal of Allergy and Clinical Immunology. in Practice|July 11, 2017
Asthma Exacerbations: Pathogenesis, Prevention, and TreatmentJamee R Castillo, Stephen P Peters, William W Busse
Current Allergy and Asthma Reports|February 11, 2004
Long-acting beta agonists in asthma therapyRichard W Rissmiller, Michael J Larj, Stephen P Peters
Respiratory Medicine|May 23, 2006
Uncontrolled asthma: a review of the prevalence, disease burden and options for treatmentStephen P Peters, Gary Ferguson, Yamo Deniz, et al.
The Journal of Allergy and Clinical Immunology|October 10, 2006
Asthma end points and outcomes: what have we learned?Don Bukstein, Monica Kraft, Andrew H Liu, et al.
Blood|November 10, 2005
Beta-agonists modulate T-cell functions via direct actions on type 1 and type 2 cellsMatthew J Loza, Susan Foster, Stephen P Peters, et al.
Pageof 21

Showing results (21-30 of 210) with videos related to

Sort By:
Pageof 21
The Journal of Allergy and Clinical Immunology|November 10, 2009
The irreversible component of persistent asthmaRodolfo M Pascual, Stephen P Peters
American Journal of Respiratory and Critical Care Medicine|March 27, 2007
Update in asthma 2006Wendy C Moore, Stephen P Peters
Current Opinion in Pharmacology|May 11, 2010
Beta-2 adrenergic agonists: focus on safety and benefits versus risksVictor E Ortega, Stephen P Peters
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|March 24, 2010
Is the maintenance and reliever approach the answer?John J Oppenheimer, Stephen P Peters
Drug Discovery Today|December 27, 2005
Novel and emerging therapies for asthmaThomas M Leath, Manav Singla, Stephen P Peters
The Journal of Allergy and Clinical Immunology. in Practice|July 11, 2017
Asthma Exacerbations: Pathogenesis, Prevention, and TreatmentJamee R Castillo, Stephen P Peters, William W Busse
Current Allergy and Asthma Reports|February 11, 2004
Long-acting beta agonists in asthma therapyRichard W Rissmiller, Michael J Larj, Stephen P Peters
Respiratory Medicine|May 23, 2006
Uncontrolled asthma: a review of the prevalence, disease burden and options for treatmentStephen P Peters, Gary Ferguson, Yamo Deniz, et al.
The Journal of Allergy and Clinical Immunology|October 10, 2006
Asthma end points and outcomes: what have we learned?Don Bukstein, Monica Kraft, Andrew H Liu, et al.
Blood|November 10, 2005
Beta-agonists modulate T-cell functions via direct actions on type 1 and type 2 cellsMatthew J Loza, Susan Foster, Stephen P Peters, et al.
Pageof 21